(RTTNews) - Moderna, Inc. (MRNA) announced Monday its agreement with Aldevron, LLC, a provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, in support of the Moderna COVID-19 Vaccine and additional programs in its clinical development pipeline.
Under the expanded deal, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna's pipeline.
The company noted that Aldevron's production of DNA continues to take place in its GMP facility located in Fargo, North Dakota. Further, Aldevron has completed buildout and validation of an additional 189,000 sq ft expansion to the GMP facility on its 14-acre Breakthrough Campus, enabling additional manufacturing capacity.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
